Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More

Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's investments in Lifeward and Scilex have yielded strong returns, including a near tripling of its $38.2M Alpha Tau Medical stake and robust loan recovery from Scilex. Alpha Tau Medical's Alpha DaRT product, with approvals in Japan and Israel and a lucrative U.S. licensing deal, offers substantial upside but faces clinical and regulatory risks.

Seeking Alpha • Sep 11, 2026

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026) Oramed to Join the Russell 2000 and Russell 3000 Indexes this week NEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).

PRNewsWire • Jun 25, 2026

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026.

PRNewsWire • Jun 17, 2026

Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction

Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for ORMD-0801 in Type 2 Diabetes. ORMP pivots to target a subset of T2D patients and transfers its POD Technology to Lifeward, securing a 49.9% stake and potential revenue streams for ReWalk. Strategic investments in biotech and real estate diversify risk, but cash burn and limited liquidity raise near-term funding concerns.

Seeking Alpha • May 22, 2026

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

GlobeNewsWire • Mar 13, 2026

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed's clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportunity POD™ targets the $600+ billion injectable drugs market, including ORMD-0801, which has the potential to become the world's first commercialized oral insulin medicine MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

GlobeNewsWire • Jan 13, 2026

Oramed and Lifeward Announce Strategic Transaction

Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical program Oramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrants Mark Grant, Lifeward CEO, with 25+ years experience in the diabetes sector at Medtronic and Bristol Myers Squibb, to lead combined platforms In addition, strategic investment by Oramed designed to bring Lifeward towards profitability Lifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in last four quarters NEW YORK, Jan. 13, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor.

PRNewsWire • Jan 13, 2026

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties.

PRNewsWire • Jan 7, 2026

Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback

Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group.

Seeking Alpha • Dec 24, 2025

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company.  The Rights are designed to assure that all stockholders of the Company receive fair and equal treatment in the event of a hostile takeover of the Company, to guard against tactics designed to gain control of the Company without paying all stockholders a fair price, and to enhance the Board's ability to negotiate with any prospective acquiror.

PRNewsWire • Nov 17, 2025